IID-11.4 Data Details

The National Immunization Survey-Teen (NIS-Teen) collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit-dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure were restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13–15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service. A recent report outlining the methodology of the NIS Surveys is available at https://www.cdc.gov/vaccines/imz-managers/nis/methods.html.

In December 2016, the ACIP updated the HPV vaccine recommendation to include a 2-dose schedule for immunocompetent adolescents initiating the vaccination series before their 15th birthday1. Three doses are still recommended for persons initiating the series at ages 15 through 26 years or who are immunocompromised1. To account for the revisions to the HPV vaccine recommendation, a new measure of being up to date with HPV vaccination was reported in the 2016 NIS-Teen MMWR article2. As measured by the NIS-Teen, an adolescent is considered up to date with the HPV vaccine series if they receive 3 or more doses of HPV vaccine, or if each of the following three conditions are met: 1) they receive 2 doses of HPV vaccine; 2) the first dose of HPV vaccine is received before their 15th birthday; and 3) the difference between dates of first and second doses is greater than or equal to 5 months minus 4 days–the absolute minimum interval between the first and second doses.

This measure tracks the proportion of female adolescents aged 13–15 years who received 2 or 3 doses of the human papillomavirus (HPV) vaccine as recommended.

References

1. 1. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016;65:1405–8.
2. 2. Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years – United States, 2016. MMWR. 2017 Aug 25;66 (33):874-82. DOI: http://dx.doi.org/10.15585/mmwr.mm6633a2.

The National Immunization Survey-Teen (NIS-Teen) collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit-dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure were restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13–15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service. A recent report outlining the methodology of the NIS Surveys is available at https://www.cdc.gov/vaccines/imz-managers/nis/methods.html.

In December 2016, the ACIP updated the HPV vaccine recommendation to include a 2-dose schedule for immunocompetent adolescents initiating the vaccination series before their 15th birthday1. Three doses are still recommended for persons initiating the series at ages 15 through 26 years or who are immunocompromised1. To account for the revisions to the HPV vaccine recommendation, a new measure of being up to date with HPV vaccination was reported in the 2016 NIS-Teen MMWR article2. As measured by the NIS-Teen, an adolescent is considered up to date with the HPV vaccine series if they receive 3 or more doses of HPV vaccine, or if each of the following three conditions are met: 1) they receive 2 doses of HPV vaccine; 2) the first dose of HPV vaccine is received before their 15th birthday; and 3) the difference between dates of first and second doses is greater than or equal to 5 months minus 4 days–the absolute minimum interval between the first and second doses.

This measure tracks the proportion of female adolescents aged 13–15 years who received 2 or 3 doses of the human papillomavirus (HPV) vaccine as recommended.

References

1. 1. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016;65:1405–8.
2. 2. Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years – United States, 2016. MMWR. 2017 Aug 25;66 (33):874-82. DOI: http://dx.doi.org/10.15585/mmwr.mm6633a2.